KRAS and non-small cell lung carcinoma: Results from a meta-analysis by Kim et al. demonstrated that immunotherapy compared to chemotherapy significantly improved OS in pretreated patients with mutated KRAS NSCLC but not in those with wild-type KRAS [21].